Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial

The Lancet

Volumn 386, Issue 9988, 2015, Pages 31-45

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; MALARIA VACCINE;

AGE; ANEMIA; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACTEREMIA; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INFANT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALNUTRITION; MENINGITIS; MORTALITY; NEWBORN; PARASITEMIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TONIC CLONIC SEIZURE; AFRICA SOUTH OF THE SAHARA; CLINICAL TRIAL; FEMALE; HOSPITALIZATION; IMMUNIZATION; INCIDENCE; MALARIA, FALCIPARUM; MALE; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA;

AFRICA SOUTH OF THE SAHARA; AGE FACTORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE;

EID: 84937422078     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60721-8     Document Type: Article

References (19)

1. WHO World Malaria Report, 2014 2014 World Health Organization Geneva
2. DM Gordon, TW McGovern, U Krzych et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine J Infect Dis 171 1995 1576 1585
3. J Cohen, V Nussenzweig, R Nussenzweig, J Vekemans, A Leach From the circumsporozoite protein to the RTS,S/AS candidate vaccine Hum Vacc 6 2010 90 96
4. KE Kester, JF Cummings, O Ofori-Anyinam et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection J Infect Dis 200 2009 337 346
5. B Lell, S Agnandji, I von Glasenapp et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon PLoS One 4 2009 e7611
6. S Owusu-Agyei, D Ansong, K Asante et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children PLoS One 4 2009 e7302
7. RTS,S Clinical Trials Partnership A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants N Engl J Med 367 2012 2284 2295
8. RTS,S Clinical Trials Partnership First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children N Engl J Med 365 2011 1863 1875
9. RTS,S Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites PLoS Med 11 2014 e1001685
10. A Leach, J Vekemans, M Lievens et al. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa Malar J 10 2011 224
11. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH harmonised tripartite guideline. Guideline for good clinical practice http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf 1996 (accessed April 22, 2015).
12. ME Molyneux, TE Taylor, JJ Wirima, A Borgstein Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children Q J Med 71 1989 441 459
13. ICH MedDRA® term selection: points to consider. ICH-endorsed guide for MedDRA users https://www.meddra.org/sites/default/files/guidance/file/9491-1610-termselptc-r4.6-sep2013.pdf 2013 (accessed April 22, 2015).
14. F Clement, V Dewar, E Van Braeckel et al. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum Malar J 11 2012 384
15. B Efron, R Tibshirani An introduction to the bootstrap 1993 Chapman & Hall New York
16. JA Scott, JA Berkley, I Mwangi et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population based, case-control study and a longitudinal study Lancet 378 2011 1316 1323
17. K Bojang, P Milligan, M Pinder et al. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia Hum Vaccin 5 2009 242 247
18. K Kester, J Cummings, O Ofori-Anyinam et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection J Infect Dis 200 2009 337 346
19. WHO WHO Initiative for vaccine research/global malaria programme joint technical expert group (JTEG) on malaria vaccines entering pivotal phase 3 trials & beyond (established April 2009) http://www.who.int/immunization/research/committees/jteg/en (accessed April 22, 2015).